Molecular Therapy: Methods & Clinical Development (Sep 2020)

A Long Intergenic Non-coding RNA, LINC01426, Promotes Cancer Progression via AZGP1 and Predicts Poor Prognosis in Patients with LUAD

  • Baorui Tian,
  • Xiaoyang Han,
  • Guanzhen Li,
  • Hua Jiang,
  • Jianni Qi,
  • Jiamei Li,
  • Yingying Tian,
  • Chuanxi Wang

Journal volume & issue
Vol. 18
pp. 765 – 780

Abstract

Read online

Various long non-coding RNAs (lncRNAs) are closely associated with lung adenocarcinoma (LUAD), playing oncogenic or anti-oncogenic roles in tumorigenesis and progression. Herein, we report a novel lncRNA—long intergenic non-protein coding RNA 1426 (LINC01426)—that has not yet been characterized in LUAD. We note that LINC01426 expression was markedly upregulated in LUAD tissues, and that functional assays verified that LINC01426 knockdown markedly inhibited cell proliferation, migration, and invasion in vitro. Xenografts derived from A549 cells knocked down of LINC01426 had evidently lower tumor weights and smaller tumor volumes. Our study also found that LINC01426 bound to hsa-miR-30b-3p as a competitive endogenous RNA in LUAD. Moreover, LINC01426 affected LUAD wound healing by interacting and combining with AZGP1, and LINC01426 expression was significantly associated with tumor-node-metastasis (TNM) staging and prognosis in patients with LUAD. To summarize, our study elucidates the oncogenic roles of LINC01426 in LUAD tumorigenesis and progression. We think that LINC01426 can serve as a potential diagnostic biomarker and therapeutic target in patients with LUAD.

Keywords